Article info
PDFLaw, ethics and medicine
Paper
Access to investigational medicinal products for minors in Europe: ethical and regulatory issues in negotiating children's access to investigational medicines
- Correspondence to Wim Pinxten, Centre for Biomedical Ethics and Law, KU Leuven, Kapucijnenvoer 35 Box 7001, BE-3000, Leuven, Belgium; wim.pinxten{at}med.kuleuven.be
Citation
Access to investigational medicinal products for minors in Europe: ethical and regulatory issues in negotiating children's access to investigational medicines
Publication history
- Received March 11, 2010
- Revised July 22, 2010
- Accepted July 26, 2010
- First published September 18, 2010.
Online issue publication
November 26, 2010
Article Versions
- Previous version (18 September 2010).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2010, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Other content recommended for you
- Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials
- Off-trial access to experimental cancer agents for the terminally ill: balancing the needs of individuals and society
- Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries
- Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program
- Children’s views on taking medicines and participating in clinical trials
- Nusinersen for SMA: expanded access programme
- Engaging African ancestry participants in SLE clinical trials
- Accessing unproven interventions in the COVID-19 pandemic: discussion on the ethics of ‘compassionate therapies’ in times of catastrophic pandemics
- Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study
- Expanded access: growing importance to public health